Testosterone for HSDD: An Evidence-Based Guide to Treating Low Female Libido

What Is HSDD?

Hypoactive sexual desire disorder (HSDD) is a clinical diagnosis defined by three core features:

1. Persistently or recurrently low or absent sexual desire, including a lack of sexual fantasies or thoughts
2. Marked personal distress caused by these symptoms—the woman herself is bothered by them
3. Not better explained by another condition, medication side effect, relationship issue, or substance use

Each criterion matters. Low sexual desire that doesn't cause distress isn't HSDD. Low desire that is fully explained by another factor (a major depressive episode, a difficult relationship, a medication side effect) is also not HSDD until those factors are addressed and the desire problem persists.

This careful definition is important because HSDD describes a clinically meaningful condition—one that affects quality of life, relationships, and self-perception—rather than a normal variation in sexual desire. Women's sexual desire varies substantially across individuals, life stages, and contexts. Lower desire than a partner has, lower desire than earlier in a relationship, or lower desire than cultural expectations suggest do not constitute disorders. HSDD specifically describes desire that is personally distressing.

How Common Is HSDD?

Population studies suggest that approximately 10 percent of U.S. women meet criteria for HSDD at any given time, though up to 40 to 44 percent of women report decreased sexual desire at some point in their lives. The prevalence increases substantially during and after the menopause transition. Surgical menopause—removal of both ovaries—often produces HSDD at higher rates and more abruptly than natural menopause.

HSDD is one of the most common forms of female sexual dysfunction, and one of the most under-recognized in primary care. Many women experience it without ever discussing it with a clinician; many clinicians don't proactively screen for it.

Why HSDD Matters Clinically

For women experiencing HSDD, the effects extend beyond sexual function. Persistent low desire can affect:

• Relationship satisfaction and intimacy
• Self-perception and sexual identity
• Mood and overall sense of well-being
• Sense of connection in long-term partnerships

These downstream effects are part of why HSDD warrants treatment when desire is distressing—not as a treatment of "normal" variation in libido, but as recognition that personally distressing low desire is a real and addressable condition.

How HSDD Is Diagnosed

The diagnosis of HSDD is clinical—based on history and assessment, not on testosterone blood levels. There is no specific testosterone level that diagnoses HSDD or that serves as a treatment target. The 2021 ISSWSH clinical practice guideline is explicit about this: a woman with HSDD may have normal testosterone levels, low testosterone levels, or testosterone levels somewhere in between. The diagnosis rests on the clinical picture.

The Biopsychosocial Assessment

The framework recommended by ISSWSH and other professional societies is a biopsychosocial assessment. This means evaluating four broad categories of factors that contribute to sexual desire:

Biological factors

• Hormonal status (estradiol, testosterone, thyroid function, prolactin)
• Genitourinary symptoms (dryness, pain with intercourse, vaginal atrophy)
• Pelvic floor dysfunction
• Chronic medical conditions
• Medications affecting sexual function

Psychological factors

• Mood disorders (depression, anxiety)
• Body image and self-perception
• History of trauma or sexual abuse
• Sexual self-confidence
• Beliefs and attitudes about sex

Interpersonal factors

• Relationship satisfaction and conflict
• Partner sexual function
• Communication patterns about sex
• Duration of relationship (long-term relationships often see naturally declining novelty-driven desire)

Sociocultural factors

• Cultural and religious beliefs about sexuality
• Stress and life demands
• Sleep deprivation and physical exhaustion
• Caregiver burden

A thorough biopsychosocial assessment looks at all four. Treating only the biological component—prescribing testosterone without addressing other contributors—often produces incomplete results.

Medications That Commonly Affect Desire

A thorough assessment includes review of medications, several of which commonly contribute to low desire:

• SSRIs and SNRIs (antidepressants) are among the most common causes of medication-induced low desire and sexual dysfunction
• Oral contraceptives can reduce free testosterone via increased SHBG and contribute to low desire in younger women
• Beta blockers and other cardiovascular medications
• Opioids chronically reduce sex hormone production
• Certain anti-androgen medications prescribed for acne or hirsutism

Addressing these factors—either by changing medications where appropriate or adjusting dosing—is often necessary before testosterone therapy is considered.

Laboratory Testing

While there is no testosterone level that diagnoses HSDD, hormone testing provides useful context:

• Total testosterone and free testosterone
• Sex hormone binding globulin (SHBG)
• Estradiol and progesterone
• DHEA-S
• Thyroid function (TSH, free T4, free T3)
• Prolactin
• Complete blood count and metabolic panel

For premenopausal women, testing on specific cycle days may be relevant. Morning testing is preferred for accuracy.

For a fuller treatment of testing in women's hormonal evaluation, see our Complete Female Hormone Panel.

The Evidence for Testosterone in HSDD

This is the area where the evidence base for testosterone in women is strongest. Multiple large randomized controlled trials, multiple meta-analyses, and formal endorsement from international medical societies all support testosterone therapy for postmenopausal women with HSDD.

The Key Trials

The INTIMATE trials (2005-2006). Two large randomized controlled trials examined testosterone patches in postmenopausal women with HSDD. The Naturally Menopausal study (INTIMATE NM1) included 549 naturally menopausal women on estrogen therapy with HSDD, randomized to testosterone patch or placebo. The Surgically Menopausal study (INTIMATE 1 and 2) included surgically menopausal women on estrogen with HSDD. Both demonstrated significant increases in satisfying sexual events, sexual desire, arousal, and orgasm with testosterone therapy compared to placebo.

Davis et al. 2008 (APHRODITE). A 52-week randomized controlled trial of 814 postmenopausal women with HSDD not taking estrogen examined testosterone patches at 150 mcg/day and 300 mcg/day versus placebo. The 300 mcg dose increased satisfying sexual activity by an average of 1.56 episodes per 4 weeks compared to 0.73 episodes with placebo—a statistically and clinically significant difference [1].

The 2019 Islam meta-analysis. Published in The Lancet Diabetes & Endocrinology, this systematic review and meta-analysis included 36 randomized controlled trials with over 8,400 women. The pooled analysis found significant benefits of testosterone therapy for sexual function across multiple endpoints in postmenopausal women with HSDD [2].

What the Trials Show

Across the evidence base, testosterone therapy in postmenopausal women with HSDD produces:

• Increased number of satisfying sexual events (the primary endpoint in most trials)
• Improved sexual desire as measured by validated questionnaires
• Improved arousal
• Improved frequency of orgasm
• Reduced sexual distress

The effect sizes are modest but clinically meaningful. The improvements are particularly substantial for women with surgical menopause, where the abrupt loss of ovarian testosterone production produces more severe symptoms than gradual natural decline.

Formal Endorsement

The 2019 Global Consensus Position Statement on testosterone therapy for women, published by ten international medical societies, formally endorses testosterone therapy for postmenopausal women with HSDD as the only well-established indication for testosterone in women [3].

The 2021 ISSWSH Clinical Practice Guideline provides the most detailed clinical framework for testosterone in HSDD, including patient selection, formulations, dosing, and monitoring [4].

The September 2025 Obstetrics & Gynecology narrative review summarizes the current state of evidence and provides updated clinical guidance for prescribing clinicians [5].

Treatment Approach: Beyond Testosterone Alone

Effective treatment of HSDD generally requires more than testosterone therapy alone. The biopsychosocial framework that guides assessment also guides treatment.

Address Identified Contributors First

Before or alongside testosterone therapy:

• Estrogen therapy for postmenopausal women with genitourinary symptoms (dryness, pain with intercourse) that may be contributing to reduced desire. The 2025 AUA Genitourinary Syndrome of Menopause guideline supports vaginal estrogen for these symptoms.
• Adjusting medications that may be contributing to low desire, particularly SSRIs/SNRIs and oral contraceptives, where clinically appropriate.
• Treatment of mood disorders if present.
• Pelvic floor physical therapy for women with pain with intercourse or pelvic floor dysfunction.
• Couples therapy or sex therapy for relationship and communication issues.

Non-Testosterone FDA-Approved Options

Two medications are FDA-approved for HSDD in premenopausal women (note: not postmenopausal, where testosterone has the strongest evidence):

Flibanserin (Addyi) is a non-hormonal daily oral medication approved for HSDD in premenopausal women. It modulates serotonin and dopamine signaling in the brain. Side effects include hypotension, dizziness, and the need to avoid alcohol. Response rates are modest.

Bremelanotide (Vyleesi) is a melanocortin receptor agonist approved for HSDD in premenopausal women, administered as a subcutaneous injection 45 minutes before anticipated sexual activity. Side effects include nausea and transient blood pressure increases.

Neither flibanserin nor bremelanotide is FDA-approved for postmenopausal women, and neither has the same effect size or evidence base as testosterone for HSDD in postmenopause.

Testosterone Therapy for HSDD

For postmenopausal women with HSDD, testosterone therapy is generally the most evidence-supported pharmacological option. The ISSWSH 2021 clinical practice guideline establishes the standard framework:

Patient selection. Postmenopausal women (natural or surgical) with HSDD diagnosed through comprehensive biopsychosocial assessment, with contraindications excluded. Some clinicians extend use to perimenopausal women with HSDD, though the evidence base in perimenopause is less developed.

Formulation. Transdermal cream is the preferred delivery method. Compounded by 503A pharmacies, applied to skin (usually inner thigh, lower abdomen, or forearm) once daily.

Dosing. Approximately one-tenth of male dosing. Typical starting dose is 0.5 mL of transdermal cream daily, with adjustment based on lab response. Goal is to maintain circulating testosterone within the normal premenopausal female range.

Monitoring. Baseline hormone panel before starting. Follow-up testosterone level at 4-6 weeks to verify therapeutic range. Periodic re-testing every 6 months. Clinical re-evaluation for response at each follow-up.

Treatment duration. Trials typically run 12-24 weeks before evaluating response. If meaningful improvement has not occurred after approximately 6 months of therapy at adequate doses, testosterone is generally discontinued.

What about pellets? Pellet therapy is not recommended for HSDD or any other indication in women. Pellets deliver testosterone levels above the female physiological range, cannot be adjusted once implanted, and are responsible for most of the documented serious side effects in women. Transdermal cream is preferred.

For a complete treatment of testosterone dosing in women, see our testosterone treatment for women guide.

What to Expect: Timing and Outcomes

Timeline for Effects

Effects on HSDD symptoms emerge gradually:

• First 2-4 weeks: Some women notice early changes in mood, energy, or sense of well-being. Sexual changes are usually not yet apparent.
• Weeks 4-8: Sexual desire may begin to shift. Many women describe increased sexual thoughts or fantasies before they notice changes in sexual activity itself.
• Weeks 8-12: Increases in satisfying sexual events, arousal, and orgasm typically emerge during this window.
• Weeks 12-24: Full effects on HSDD symptoms generally develop. The major trials measured outcomes at 24 weeks and beyond.
• Beyond 6 months: Continued use maintains the effect for most responders.

Response Rates and Realistic Expectations

Response to testosterone for HSDD is variable. Major trials have shown:

• Approximately 30-50 percent of women achieve meaningful clinical improvement on testosterone therapy
• The average increase in satisfying sexual events is approximately 1 additional event per month over placebo
• Some women experience substantial improvement; others experience modest improvement; a meaningful minority do not respond
• No reliable predictor exists for who will respond well

The realistic framing: testosterone therapy is the most evidence-supported pharmacological treatment for HSDD, but it is not universally effective. For women who don't respond, the answer is often to revisit the biopsychosocial assessment rather than to increase the dose.

When Testosterone Doesn't Work

For women whose HSDD doesn't improve adequately on testosterone:

• Revisit the biopsychosocial assessment. Were relationship, psychological, or medical contributors fully addressed?
• Check the dose and absorption. Are testosterone levels actually in the target range? Some women absorb transdermal cream poorly.
• Consider co-administered therapies. Estrogen therapy for genitourinary symptoms; psychological or relationship interventions; addressing medication interactions.
• Consider whether HSDD is the correct diagnosis. Sexual dysfunction has many causes; sometimes the original diagnosis warrants reconsideration.
• Accept that some HSDD doesn't respond. As with most conditions, treatment doesn't help everyone, and that is not a treatment failure—it is information about that individual's biology.

Side Effects and Safety

At physiologic doses with appropriate monitoring, testosterone therapy for HSDD is generally well-tolerated. Side effects are usually mild and reversible at proper doses.

Possible side effects:

• Mild acne (most common, usually responds to dose reduction)
• Slight increase in body or facial hair (most common in genetically predisposed women)
• Mild hair changes (scalp thinning or increased oiliness)
• Voice changes (rare at physiologic doses; can be irreversible if dose not promptly reduced)
• Mood changes (usually positive, occasionally irritability)
• Clitoral enlargement (rare at physiologic doses; can be irreversible if not addressed)
• Application site reaction for transdermal preparations

Contraindications:

• Pregnancy or breastfeeding
• Active hormone-sensitive cancer (breast, endometrial) without specialist input
• Severe acne or significant baseline hirsutism
• Polycystic ovary syndrome (PCOS) with elevated baseline androgens
• Active liver disease
• Trying to conceive

Cardiovascular safety. The 2024 Davis et al. observational study found that higher testosterone in postmenopausal women was associated with better lipid profiles—higher HDL and lower triglycerides—suggesting testosterone within the female physiological range is not adverse to cardiovascular health [6]. Long-term cardiovascular trial data in women are still limited.

The single most important safety principle is maintaining testosterone levels within the female physiological range. Most serious documented side effects in women have occurred at supraphysiologic doses, particularly with pellet therapy.

HSDD in Premenopausal Women

The evidence base for testosterone in HSDD is strongest in postmenopausal women, but some premenopausal women also experience HSDD and may benefit from testosterone therapy.

The key considerations:

• The trial evidence is less developed in premenopausal women. The major HSDD trials focused on postmenopausal populations.
• Premenopausal women on oral contraceptives often have reduced free testosterone due to elevated SHBG. Addressing the contraceptive method may resolve symptoms without requiring testosterone therapy.
• Reproductive intent must be considered. Testosterone is contraindicated for women trying to conceive, breastfeeding, or pregnant. Premenopausal use generally requires reliable non-hormonal contraception.
• Cycle-related fluctuations in hormones can affect both the symptom picture and the assessment.

For premenopausal women with HSDD that has not responded to addressing other factors, testosterone therapy under close physician supervision may be reasonable, with full disclosure of the more limited evidence base in this population.

Frequently Asked Questions

What is HSDD?

Hypoactive sexual desire disorder (HSDD) is a clinical condition defined by persistent or recurrent absence of sexual fantasies and desire that causes marked personal distress and is not better explained by another medical condition, medication side effect, or relationship issue. It is one of the most common forms of female sexual dysfunction, affecting approximately 10 percent of U.S. women at any given time.

Is testosterone therapy effective for HSDD?

Yes. Testosterone therapy is the most evidence-supported pharmacological treatment for HSDD in postmenopausal women. Multiple randomized controlled trials and a meta-analysis of over 8,400 women have demonstrated significant improvements in satisfying sexual events, sexual desire, arousal, and orgasm. The effect sizes are modest but clinically meaningful, and approximately 30 to 50 percent of women experience meaningful clinical improvement.

How long does testosterone take to work for HSDD?

Effects emerge gradually over weeks to months. Some women notice early changes in mood and well-being within 2 to 4 weeks. Sexual desire changes often emerge over 4 to 8 weeks. Full effects on satisfying sexual events and overall sexual function typically develop over 12 to 24 weeks. Most clinicians evaluate response at approximately 6 months.

Is HSDD just low libido?

No. HSDD specifically requires that the low desire causes marked personal distress and is not better explained by other factors. Many women have low or fluctuating libido that doesn't meet HSDD criteria. The distress component is essential—it distinguishes a clinical condition from a normal variation in sexual desire.

Can premenopausal women have HSDD?

Yes. HSDD occurs in women across the reproductive lifespan, though it is most common during and after the menopause transition. Premenopausal women can experience HSDD, though the formal trial evidence for testosterone in premenopausal HSDD is less developed than for postmenopausal HSDD.

What's the dose of testosterone for HSDD?

Typically a transdermal cream applied to skin daily, with doses approximately one-tenth of male dosing. A common starting dose is 0.5 mL daily, with adjustment based on lab response. The goal is to maintain blood testosterone within the normal premenopausal female range.

Are there non-testosterone treatments for HSDD?

Yes. The FDA has approved two medications specifically for HSDD in premenopausal women: flibanserin (Addyi), a daily oral medication, and bremelanotide (Vyleesi), an on-demand subcutaneous injection. Neither is approved for postmenopausal women. Estrogen therapy can address genitourinary symptoms that contribute to low desire. Psychological and relationship interventions are often essential components of HSDD treatment.

What is the biopsychosocial approach to HSDD?

A framework for evaluating and treating HSDD that addresses biological factors (hormones, medical conditions, medications), psychological factors (mood, body image, history of trauma), interpersonal factors (relationship dynamics, partner sexual function), and sociocultural factors (cultural beliefs, life stress). Effective HSDD treatment typically addresses all four rather than treating any single factor in isolation.

Does testosterone help libido in premenopausal women?

The evidence is more limited than in postmenopausal women. Some premenopausal women with HSDD do respond to testosterone therapy, but the trial data are less developed. For premenopausal women on oral contraceptives, addressing the contraceptive method may resolve low libido without requiring testosterone therapy.

How is HSDD diagnosed?

Through clinical assessment combining history, symptom evaluation, and ruling out other potential causes. There is no testosterone level that diagnoses HSDD or that serves as a treatment target. The diagnosis rests on the clinical picture: persistent or recurrent low or absent sexual desire that causes marked personal distress and is not better explained by another condition, medication, or relationship issue.

Can SSRIs cause low libido?

Yes. SSRIs and SNRIs (selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors) are among the most common causes of medication-induced low desire and sexual dysfunction. Women whose low desire emerged after starting an SSRI should discuss this with their prescribing clinician, as alternative medications or dose adjustments may help.

Will birth control affect my libido?

For many women, yes. Many oral contraceptives increase sex hormone binding globulin (SHBG), which binds testosterone and reduces the biologically active free fraction. The result is that women on oral contraceptives often have lower free testosterone, which can contribute to reduced libido. For women with libido changes that emerged after starting hormonal contraception, discussing alternatives with the prescribing clinician is reasonable.

Is testosterone safe long-term for HSDD?

At physiologic doses with appropriate monitoring, testosterone therapy is generally well-tolerated long-term. Major trials have followed women on testosterone for up to 52 weeks with favorable safety profiles. Long-term safety beyond several years has not been formally established by randomized trials, though clinical experience over decades has not surfaced major safety signals when therapy is properly conducted.

Where can I get testosterone therapy for HSDD?

Testosterone therapy for HSDD is available through gynecologists, urologists with women's sexual health focus, endocrinologists, menopause specialists, sexual medicine specialists, integrative medicine practitioners, and women's-health-focused telemedicine providers. The key consideration is finding a clinician familiar with women's testosterone therapy, comfortable with the biopsychosocial approach to HSDD, and willing to monitor appropriately. Healthspan offers testosterone therapy through our Women's Hormone Health Program.

How Healthspan Approaches HSDD and Female Libido

The Healthspan Women's Hormone Health Program provides physician-supervised evaluation and treatment for women with HSDD and related sexual health concerns. Our approach reflects the biopsychosocial framework that current evidence supports:

• Comprehensive evaluation. Detailed history, assessment of symptoms, evaluation of contributing factors (relationship, psychological, medical, hormonal), and review of medications
• Hormone testing. Our Complete Female Hormone Panel provides comprehensive assessment of testosterone, estradiol, progesterone, DHEA-S, thyroid function, and other relevant markers
• Differential diagnosis. Evaluation of other potential contributors to low desire so treatment addresses the actual causes
• Personalized treatment. When testosterone therapy is indicated, prescription as compounded transdermal cream at individualized dosing
• Coordinated care. For perimenopausal and postmenopausal women, integration of testosterone with estrogen and progesterone therapy when indicated
• Ongoing monitoring. Follow-up labs and clinical evaluation at 4-6 weeks and every 6 months thereafter
• Referrals when appropriate. For psychological, relationship, or sexual medicine concerns requiring specialist input

Membership pricing for the Women's Hormone Health Program starts at $99 per month on a three-month plan or $129 for a single month. Lab work and medication are billed separately when prescribed.

We are one of several legitimate options for women considering testosterone therapy for HSDD. The right path depends on existing care relationships, symptom severity, and individual preference.

Conclusion

Hypoactive sexual desire disorder is a real and addressable condition. For women whose low sexual desire causes personal distress, evidence-based treatment options exist, and the medical understanding of HSDD has matured significantly over the past two decades.

Testosterone therapy is the most evidence-supported pharmacological treatment for HSDD in postmenopausal women. Multiple major trials, a meta-analysis of over 8,400 women, and formal endorsement by international medical bodies all support its use in this specific indication. The clinical framework—biopsychosocial assessment, physiologic dosing, ongoing monitoring—has been well-established by professional society guidelines.

What testosterone therapy is not is a one-size-fits-all solution. HSDD has many contributors, and effective treatment usually addresses several of them together. Testosterone is one component of comprehensive care, alongside addressing relationship factors, psychological contributors, medication effects, and other medical issues. The biopsychosocial framework that guides assessment also guides treatment.

For women experiencing distressing low sexual desire, the next step is comprehensive evaluation with a clinician familiar with HSDD assessment and treatment. The evidence supports testosterone therapy when appropriate—and the framework for prescribing it safely and effectively is well-established.

Related Research

• Testosterone Treatment for Women: A Comprehensive Guide
• Testosterone Therapy for Menopause
• Low Testosterone in Women: Signs, Causes, and Treatment
• The Case for Combining HRT and GLP-1s: A New Framework for Menopausal Healthspan
• Women's Hormone Health Program
• Testosterone Topical Cream
• Complete Female Hormone Panel